Access brought to you by: LOCKSS

Breast Cancer

Neoadjuvant Systemic Therapy: Promising Experimental Model or Improved Standard of Care?
Profiling Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Targetable Genetic Alterations
The UK START Trials: 10-Year Follow-Up Results
Effectiveness of Letrozole Compared with Tamoxifen for Patients with Lobular Carcinoma in the BIG 1–98 Trial
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab after Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up
Neurocognitive Impact in Adjuvant Chemotherapy for Breast Cancer Linked to Fatigue: A Prospective Functional MRI Study
ATLAS: 10 versus 5 Years of Adjuvant Tamoxifen in ER-Positive Disease
CONFIRM Trial Final Analysis of Overall Survival: Fulvestrant 500 versus 250 mg
Neoadjuvant Chemotherapy in Women 35 and Under
Sentinel Lymph Node Biopsy before or after Neoadjuvant Chemotherapy: Final Results from the SENTINA Trial

Pages